Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398188 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
A Phase 3 study of Central Abdominal Bulging, sponsored by Evofem.
- Completed
- Registry status
- Phase 3
- Development phase
- 793
- Enrollment target
- 20
- Study locations
NCT02398188 is a Phase 3 study of Central Abdominal Bulging that has completed, run by Evofem. The registered enrollment target is 793 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT02398188, a Phase 3 study of Central Abdominal Bulging, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 793 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LIPO-202
Study Locations (20)
California
- Stoll Dermatology of Beverly Hills - Beverly Hills
- Diagnamics, Inc. - Encinitas
- Ablon Skin Institute And Research Center - Manhattan Beach
- Dermatology Specialists, Inc. - Oceanside
- Rancho Mirage Dermatology - Rancho Mirage
- Faces Plus - San Diego
- Therapeutics Clinical Research - San Diego
- Syrentis Clinical Research - Santa Ana
Florida
- Altus Research - Lake Worth
- The Miami Institute - Miami
- Baumann Cosmetic and Research Institute - Miami
- Miami Research Associates - South Miami
- Clinical Research of West Florida, Inc. - Tampa
Indiana
- Laser and Skin Surgery Center of Indiana - Carmel
- South Bend Clinic - South Bend
Alabama
- Total Skin and Beauty Dermatology Center - Birmingham
Colorado
- Colorado Medical Research Center - Denver
Connecticut
- The Savin Center, PC - New Haven
Illinois
- DeNova Research - Chicago
Massachusetts
- SkinCare Physicians - Chestnut Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 793 participants |
| Start Date | 2015-04-09 |
| Est. Completion | 2015-10-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398188
The ClinicalTrials.gov registry entry for NCT02398188 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 793 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Evofem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Abdominal Bulging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02398188 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT02398188 about?
NCT02398188 is a clinical study titled "Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)". This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
What is the current status of trial NCT02398188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 793 participants. The study started on 2015-04-09. Estimated completion is 2015-10-29.
What conditions does trial NCT02398188 study?
This clinical trial studies the following conditions: Central Abdominal Bulging.
What interventions are being tested in trial NCT02398188?
The interventions under investigation include: Placebo (DRUG), LIPO-202 (DRUG).
Who is sponsoring clinical trial NCT02398188?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02398188 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.